Your front row seat to the future of biopharma
The Institute@Precision was created to bring together the people driving discovery, development, and delivery, and to turn their collective experience into shared insight. This isn't just thought leadership - it's a collaborative space for learning, connecting, and accelerating progress across the entire precision ecosystem.
Q4 2025 Topic: ADCs
ADCs Deep Dive
Since the first ADC approval 25 years ago, they have revolutionized oncology treatment. What can we learn from a quarter century of R&D breakthroughs and failures, and from the commercialization and access strategies these drugs have used?
1H 2026 Topic: Radiopharmaceuticals
Radiopharmaceuticals Deep Dive
Radiopharmaceuticals present enormous promise for the next generation of oncology treatments. How can we address the clinical, logistical, manufacturing, and other challenges these therapies present?
Q4 2025 Topic: ADCs
HEOR Value demonstration for Antibody-Drug Conjugates: Lessons learned from the first 25 years
Q4 2025 Topic: ADCs
Moving ADCs to the Front Line: Perspectives from FDA Oncology Experts
Q4 2025 Topic: ADCs
Twenty-Five Years of Antibody–Drug Conjugates: From Breakthroughs to Access by Design
Q4 2025 Topic: ADCs
The ADC Pendulum: Following the Arc from Approval to Withdrawal and Renewed Promise
Q4 2025 Topic: ADCs
Market Outlook Q4 2025: Antibody-Drug Conjugates (ADCs)
Featured content on ADCs:
HEOR Value demonstration for Antibody-Drug Conjugates: Lessons learned from the first 25 years
Moving ADCs to the Front Line: Perspectives from FDA Oncology Experts
Twenty-Five Years of Antibody–Drug Conjugates: From Breakthroughs to Access by Design
Featured content
How Health Systems Are Using AI In Clinical Decision-Making
Artificial intelligence (AI) is significantly transforming the healthcare sector, evolving from a tool used to streamline administrative tasks to one influencing essential clinical functions. For pharmaceutical manufacturers, understanding how their health system customers are using AI is crucial.
Utilization of Multiparameter Flow Cytometry for Immune Monitoring of Tumor Infiltrating Lymphocytes Isolated from Fresh Tumor Tissue
Understanding the role of infiltrating lymphocytes into tumors during clinical trials can provide insights into the complex interplay between the immune system and tumor microenvironment during treatment with novel immuno-oncology therapeutics.
PD-L1 Expression on Immune Cells from Solid Tumor Patients: Implications for Tumor Immunity and Immunotherapy
Programmed death-ligand 1 (PD-L1) is a key immune checkpoint molecule that regulates immune responses by binding to PD-1 on T cells, contributing to immune tolerance and suppression